Tags

Type your tag names separated by a space and hit enter

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Am J Kidney Dis 2005; 45(3):485-93AJ

Abstract

BACKGROUND

Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. In the Diabetes Atherosclerosis Intervention Study (DAIS), treatment of people with type 2 diabetes with micronized fenofibrate for an average of 38 months reduced the progression of angiographically evaluated coronary artery disease and improved lipoprotein level abnormalities compared with placebo. The aim of this analysis is to study the influence of the treatment on changes in urinary albumin excretion.

METHODS

Microalbuminuria was measured on 2 to 3 occasions by using timed overnight samples at baseline and yearly thereafter in 314 DAIS participants (77 women, 237 men; average age, 56 years); all except 3 participants had either a normal albumin excretion rate (<20 microg/min; n = 214) or microalbuminuria (albumin, 20 to 200 microg/min; n = 97) before randomization. Tabulated shifts (between normal, microalbuminuria, and macroalbuminuria) from baseline to last observed values were compared between treatment groups by means of chi-square or Fisher's exact test.

RESULTS

Fenofibrate significantly reduced the worsening of albumin excretion (fenofibrate, 8% versus placebo, 18%; P < 0.05). This effect was caused mostly by reduced progression from normal albumin excretion to microalbuminuria: 3 of 101 participants in the fenofibrate group versus 20 of 113 participants in the placebo group (P < 0.001). Overall, changes in albumin excretion were independent of age or changes in lipid or creatinine levels, weight, or blood pressure.

CONCLUSION

Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria.

Authors+Show Affiliations

Department of Clinical Research and Medical Affairs, Fournier Pharma, Daix, France. jc.ansquer@fr.fournierpharma.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15754270

Citation

Ansquer, Jean-Claude, et al. "Fenofibrate Reduces Progression to Microalbuminuria Over 3 Years in a Placebo-controlled Study in Type 2 Diabetes: Results From the Diabetes Atherosclerosis Intervention Study (DAIS)." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, vol. 45, no. 3, 2005, pp. 485-93.
Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485-93.
Ansquer, J. C., Foucher, C., Rattier, S., Taskinen, M. R., & Steiner, G. (2005). Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 45(3), pp. 485-93.
Ansquer JC, et al. Fenofibrate Reduces Progression to Microalbuminuria Over 3 Years in a Placebo-controlled Study in Type 2 Diabetes: Results From the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485-93. PubMed PMID: 15754270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). AU - Ansquer,Jean-Claude, AU - Foucher,Christelle, AU - Rattier,Stephanie, AU - Taskinen,Marja-Riitta, AU - Steiner,George, AU - ,, PY - 2005/3/9/pubmed PY - 2005/10/14/medline PY - 2005/3/9/entrez SP - 485 EP - 93 JF - American journal of kidney diseases : the official journal of the National Kidney Foundation JO - Am. J. Kidney Dis. VL - 45 IS - 3 N2 - BACKGROUND: Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. In the Diabetes Atherosclerosis Intervention Study (DAIS), treatment of people with type 2 diabetes with micronized fenofibrate for an average of 38 months reduced the progression of angiographically evaluated coronary artery disease and improved lipoprotein level abnormalities compared with placebo. The aim of this analysis is to study the influence of the treatment on changes in urinary albumin excretion. METHODS: Microalbuminuria was measured on 2 to 3 occasions by using timed overnight samples at baseline and yearly thereafter in 314 DAIS participants (77 women, 237 men; average age, 56 years); all except 3 participants had either a normal albumin excretion rate (<20 microg/min; n = 214) or microalbuminuria (albumin, 20 to 200 microg/min; n = 97) before randomization. Tabulated shifts (between normal, microalbuminuria, and macroalbuminuria) from baseline to last observed values were compared between treatment groups by means of chi-square or Fisher's exact test. RESULTS: Fenofibrate significantly reduced the worsening of albumin excretion (fenofibrate, 8% versus placebo, 18%; P < 0.05). This effect was caused mostly by reduced progression from normal albumin excretion to microalbuminuria: 3 of 101 participants in the fenofibrate group versus 20 of 113 participants in the placebo group (P < 0.001). Overall, changes in albumin excretion were independent of age or changes in lipid or creatinine levels, weight, or blood pressure. CONCLUSION: Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria. SN - 1523-6838 UR - https://www.unboundmedicine.com/medline/citation/15754270/Fenofibrate_reduces_progression_to_microalbuminuria_over_3_years_in_a_placebo_controlled_study_in_type_2_diabetes:_results_from_the_Diabetes_Atherosclerosis_Intervention_Study__DAIS__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0272638604014672 DB - PRIME DP - Unbound Medicine ER -